Geode Capital Management LLC Boosts Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Geode Capital Management LLC increased its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 5.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 960,767 shares of the medical instruments supplier’s stock after acquiring an additional 46,409 shares during the period. Geode Capital Management LLC owned about 2.36% of AngioDynamics worth $7,477,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Quarry LP lifted its position in shares of AngioDynamics by 75.1% during the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 2,594 shares in the last quarter. CWM LLC increased its stake in AngioDynamics by 981.3% during the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after buying an additional 8,832 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in AngioDynamics during the 3rd quarter worth approximately $86,000. SG Americas Securities LLC acquired a new stake in AngioDynamics during the 3rd quarter worth approximately $103,000. Finally, Mackenzie Financial Corp purchased a new position in AngioDynamics in the 2nd quarter valued at approximately $80,000. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Canaccord Genuity Group cut their price objective on AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, October 4th. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a research note on Tuesday, December 10th.

Insider Transactions at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer bought 20,000 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were acquired at an average price of $6.03 per share, with a total value of $120,600.00. Following the transaction, the chief executive officer now owns 681,582 shares of the company’s stock, valued at approximately $4,109,939.46. The trade was a 3.02 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders acquired 22,568 shares of company stock valued at $135,847. 5.40% of the stock is currently owned by corporate insiders.

AngioDynamics Stock Down 2.0 %

NASDAQ ANGO opened at $8.98 on Friday. AngioDynamics, Inc. has a 52 week low of $5.26 and a 52 week high of $9.58. The firm has a 50 day moving average of $7.73 and a two-hundred day moving average of $7.21. The stock has a market capitalization of $364.89 million, a PE ratio of -1.47 and a beta of 0.68.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The firm had revenue of $67.50 million during the quarter, compared to the consensus estimate of $67.93 million. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. The company’s revenue was down 14.2% compared to the same quarter last year. On average, equities research analysts expect that AngioDynamics, Inc. will post -0.41 earnings per share for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.